Pheochromocytoma surgery

Jump to navigation Jump to search

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma surgery On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma surgery

CDC on Pheochromocytoma surgery

Pheochromocytoma surgery in the news

Blogs on Pheochromocytoma surgery

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Surgery is the mainstay of treatment for pheochromocytoma.

Surgery

  • Surgical resection is the treatment of choice for benign localized tumor.
  • Given the complexity of perioperative management, and the potential for catastrophic intra and postoperative complications, such surgery should be performed only at centers experienced in the area.
  • It may also be nescessary to perform a complete surgical resection of the affected adrenal gland(s).

Adrenalictomy:

  • Laparoscopic transabdominal and retroperitoneal approaches have been used successfully for non-metastatic abdominal pheochromocytmas.[1]
  • Complicationa are less in laparoscopic than open surgery. Catecholamine secretion falls to normal level within a week. Major intraoperative complications include: intraoperative tumor capsule rupture, hypertensive crisis, myocardial infarctions, or cerebrovascular haemorrhages. Hyperdynamic instability after tumor resection is poosible. Hypoglycemia can occur after tumour resection due to unopposed insulin effect after decline of catecholamines levels.[2]
  • Severe hypotension can occur after removal of the gland due to decreased catecholamines level in blood and downregulation of adrenergic receptors. It can be controlled by vasopressors induction.[3]
  • Risk factors for complications during surgery: high plasma NE concentration, larger tumor size, postural hypotension after α-blockade, and a MAP above 100 mm Hg.

Prognosis

  • Good prognosis pateints include: small tumor size, short duration of surgery, systolic blood pressure less than 160 mmhg, and low levels of urinary catecholamines.[4]
  • Postoperative hypotension can be avoided by adequate fluid replacement.
  • Recurrence is more in patients with familial pheochromocytoma and extraadrenal tumors.[5]
  • Familial pheochromocytoma  have a high incidence of bilateral disease.
  • Partial adrenalectomy is recommended for these patients with bilateral pheochromocytomas to prevent permanent glucocorticoid deficiency.
  • Complete bilateral adrenalectomy is recommended for MEN2 patients. There is highrt rate of reccurence than in sporadic cases. Follow up for long duration after surgery is needed. Most patients should have annual biochemical screening.

References

  1. Nehs MA, Ruan DT (2011). "Minimally invasive adrenal surgery: an update". Curr Opin Endocrinol Diabetes Obes. 18 (3): 193–7. doi:10.1097/MED.0b013e32834693bf. PMID 21494137.
  2. Rafat C, Zinzindohoue F, Hernigou A, Hignette C, Favier J, Tenenbaum F; et al. (2014). "Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery". J Clin Endocrinol Metab. 99 (12): E2681–5. doi:10.1210/jc.2014-1975. PMID 25188716.
  3. Flávio Rocha M, Faramarzi-Roques R, Tauzin-Fin P, Vallee V, Leitao de Vasconcelos PR, Ballanger P (2004). "Laparoscopic surgery for pheochromocytoma". Eur Urol. 45 (2): 226–32. PMID 14734011.
  4. Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC; et al. (2010). "Trends in adrenalectomy: a recent national review". Surg Endosc. 24 (10): 2518–26. doi:10.1007/s00464-010-0996-z. PMID 20336320.
  5. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G (2001). "Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center". J Clin Endocrinol Metab. 86 (4): 1480–6. doi:10.1210/jcem.86.4.7392. PMID 11297571.


Template:WikiDoc Sources